Cargando…
Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report
BACKGROUND: Approximately 50 % of malignant melanomas harbor activating point mutations in the BRAF gene. Typically, these mutations result in the substitution of the amino acid valine at codon 600 of the gene, and 90–95 % of mutations are either BRAF(V600E) or BRAF(V600K). Specific BRAF inhibitors...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890269/ https://www.ncbi.nlm.nih.gov/pubmed/27255157 http://dx.doi.org/10.1186/s13256-016-0953-0 |